Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
GlaxoSmithKline ( (GB:GSK) ) has issued an announcement.
GSK has announced the purchase of 495,245 of its own ordinary shares as part of its ongoing buyback program, executed through its broker, Merrill Lynch International. This transaction, which took place on 12 August 2025, is part of a larger initiative that has seen the company repurchase over 22 million shares since June 2025. The shares will be held as treasury shares, impacting the company’s voting rights and share capital structure, with implications for shareholder interests and market positioning.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline’s overall stock score is driven by strong financial performance and positive corporate events, such as strategic buybacks and executive share acquisitions. While technical indicators suggest a neutral trend, the company’s balanced valuation and positive earnings call outlook contribute to a favorable investment profile.
To see Spark’s full report on GB:GSK stock, click here.
More about GlaxoSmithKline
GlaxoSmithKline (GSK) is a global healthcare company that specializes in pharmaceuticals, vaccines, and consumer healthcare products. The company focuses on research and development to provide innovative solutions in the healthcare industry, with a market presence spanning across various regions worldwide.
Average Trading Volume: 8,943,817
Technical Sentiment Signal: Hold
Current Market Cap: £56.62B
See more data about GSK stock on TipRanks’ Stock Analysis page.